Genzyme Expands - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Genzyme Expands

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Cambridge, MA (June 7)—Genzyme Corp. is growing, with a new biomanufacturing plant planned and other expansions nearing completion.

The company is investing EUR105 million (nearly $140 million) in a new 140,000-ft2 biomanufacturing plant in Lyon, France to replace its smaller plant in nearby Marcy l’Etoile. The new plant, which will be used to manufacture Genzyme’s transplantation treatment “Thymoglobulin,” will have more than twice the manufacturing capacity of the Marcy facility and will create as many as 50 new jobs. The facility’s nine-acre site leaves room for expansion should demand for Thymoglobulin continue to rise.

Genzye also is completing development of a new plant in Belgium, which will be used to produce monoclonal antibodies and proteins. The company intends to expand other facilities, including its Allston Landing protein manufacturing plant in Boston.  In addition, a new filling and packaging facility at Genzyme’s manufacturing site in Ireland recently received regulatory approvals.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here